Showing results (111-120 of 477) with videos related to
Sort By:
Pageof 48
Stroke|January 24, 2004
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic eventsPeter A Ringleb, Deepak L Bhatt, Alan T Hirsch, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|March 15, 2003
Integrin alphaIIbbeta3 and its antagonismMartin J Quinn, Tatiana V Byzova, Jun Qin, et al.Lancet (London, England)|June 20, 2003
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trialsDeepak P Vivekananthan, Marc S Penn, Shelly K Sapp, et al.Health Communication|February 7, 2013
Characteristics of genomic test consumers who spontaneously share results with their health care providerBurcu F Darst, Lisa Madlensky, Nicholas J Schork, et al.Journal of Lipid Research|February 5, 2008
Identification of a novel locus for triglyceride on chromosome 1p31-32 in families with premature CAD and MISara Bretschger Seidelmann, Lin Li, Gong-Qing Shen, et al.Journal of the American College of Cardiology|March 26, 2003
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular diseasePatricia A Gum, Kandice Kottke-Marchant, Patricia A Welsh, et al.Medical Teacher|May 9, 2022
How podcasts teach: A comprehensive analysis of the didactic methods of the top hundred medical podcastsEllen Zhang, Nicolas Trad, Robert Corty, et al.Personalized Medicine|June 23, 2011
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?Elizabeth O Lillie, Bradley Patay, Joel Diamant, et al.The Journal of Invasive Cardiology|July 11, 2007
Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trialSorin J Brener, Steven R Steinhubl, Peter B Berger, et al.American Heart Journal|February 3, 2009
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trialHerbert D Aronow, Steven R Steinhubl, Danielle M Brennan, et al.Pageof 48